US EditionCELECOR COMPLETES MULTINATIONAL PHASE 3 REGISTRATIONAL STUDY OF NOVEL ANTI-PLATELET AGENT FOR HEART ATTACK
- On May 27, 2025, in Del Mar, California, CeleCor Therapeutics announced the conclusion of the international Phase 3 CeleBrate trial evaluating Disaggpro, an anti-platelet medication for treating STEMI heart attacks.
- The trial arose from the need to improve rapid treatment at the first medical contact to open blocked arteries quickly and reduce death and heart damage.
- The randomized, placebo-controlled trial enrolled 2,463 STEMI patients at 45 sites across the US, Canada, Mexico, and Europe, administering Disaggpro by subcutaneous injection in ambulances.
- Disaggpro acts within 10-15 minutes, blocks platelet receptors to prevent clotting, and has a half-life around one hour, with effects wearing off within two hours, says inventor Barry Coller.
- The study data will unblind and analyze by Q3 2025, with results presented at a major meeting and filings for regulatory approval expected to follow.
Insights by Ground AI
Does this summary seem wrong?
11 Articles
11 Articles
All
Left
1
Center
3
Right
CeleCor Completes Phase 3 Clinical Trial of Anti-Platelet Agent for Heart Attack
CeleCor Therapeutics has completed its multinational Phase 3 clinical trial of Disaggpro (zalunfiban), an investigational heart-attack drug designed for rapid use at first point of medical contact – including before patients reach the hospital.
Coverage Details
Total News Sources11
Leaning Left1Leaning Right0Center3Last UpdatedBias Distribution75% Center
Bias Distribution
- 75% of the sources are Center
75% Center
L 25%
C 75%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage